ClinicalTrials.gg
AvailableNCT04853602Updated Aug 12, 2024

IFx-Hu2.0 Expanded Access Program

An expanded access record providing IFx-Hu2.0 in Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV and Merkel Cell Carcinoma, sponsored by TuHURA Biosciences, Inc.. Available. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by TuHURA Biosciences, Inc. · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients · Treatment IND/protocol
Ages
18 Years and older
Sex
All
01

Study summary

Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or advanced cutaneous squamous cell carcinoma (cSCC) who have failed all available treatment options.

To request access, use Responsible Party contact information provided in this record..

02

Conditions studied

  • Cutaneous Melanoma, Stage III
  • Cutaneous Melanoma, Stage IV
  • Merkel Cell Carcinoma
  • Cutaneous Squamous Cell Carcinoma

Keywords

  • CM
  • MCC
  • cSCC
  • pDNA
  • plasmid DNA
  • pAc/emm55
  • IFx-Hu.20
  • Immunotherapy
  • Gene Therapy
  • Immunology
  • Oncology
  • Immuno-Oncology
03

In context

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Lead sponsor

TuHURA Biosciences, Inc. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To request more information use Responsible Party contact information provided in this record

Exclusion criteria

Exclusion Criteria:

  • To request more information use Responsible Party contact information provided in this record
05

Access details

Study type
Expanded access
Access type
Individual patients · Treatment IND/protocol

Available treatment

  • BiologicalpDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0Studies of pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer. Therapeutic Classification: * Immunomodulatory Agent Route of Administration: * Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions) Mechanism of Action: * Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells. Physiological Effect: * Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses. In addition to priming anti-tumor immunity in immune checkpoint inhibitor (ICI)-naïve patients, this could re-sensitize patients with primary or secondary ICI clinical resistance.

    Also known as: pAc/emm55

06

Where to request access

No study locations are listed for this record.

07

References and documents

Publications

  • Bunch BL, Kodumudi KN, Scott E, Morse J, Weber AM, Berglund AE, Pilon-Thomas S, Markowitz J. Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model. Cancer Immunol Immunother. 2020 Dec;69(12):2465-2476. doi: 10.1007/s00262-020-02634-4. Epub 2020 Jun 18. PubMed 32556443 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04853602
Lead sponsor
TuHURA Biosciences, Inc.
Responsible party
Sponsor
First posted
Apr 21, 2021
Last update
Aug 12, 2024

Study contacts

James A Bianco, MD
Contact
jbianco@tuhurabio.com
813-875-6600 ext. 104
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion